Randomized Double-blind Placebo-controlled, Parallel, Multi Centre Clinical Trial of Sublingual Bacterial Vaccine in Children With Recurrent Bronchospasm (Wheezing Attacks) for the Evaluation of Efficacy, Security and Clinical Impact.
Phase of Trial: Phase III
Latest Information Update: 01 Mar 2018
Price : $35 *
At a glance
- Drugs MV 130 (Primary)
- Indications Bronchospasm
- Focus Registrational; Therapeutic Use
- Acronyms MV130
- Sponsors Inmunotek
- 12 Jan 2018 Status changed from active, no longer recruiting to completed.
- 22 Dec 2015 Planned End Date changed from 1 Nov 2016 to 1 May 2016, according to ClinicalTrials.gov record.
- 22 Dec 2015 Planned primary completion date changed from 1 Nov 2015 to 1 May 2016, according to ClinicalTrials.gov record.